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Abstract – MHC class I and II molecules are immunoregulatory cell surface glycoproteins,
which selectively bind to and present antigenic peptides to T-lymphocytes. Murine and human
studies show that variable peptide binding afﬁnity to MHC II molecules inﬂuences Th1/Th2
responses by inducing distinctive cytokine expression. To examine the biological effects of
peptidebindingafﬁnitytobovineMHC(BoLA),variousselfpeptides(BoLA-DQandﬁbrinogen
fragments) and non-selfpeptidesfromovalbumin(OVA),as wellas VP2 and VP4 peptidesfrom
foot and mouth disease virus (FMD-V) were used to (1) determine binding afﬁnities to the
BoLA-DRB3*2703 allele, previously associated with mastitis susceptibility and (2) determine
whether peptidebindingafﬁnityinﬂuences T-lymphocytefunction. Peptidebindingafﬁnitywas
determined by a competitive assay using high afﬁnity biotinylated self-peptide incubated with
puriﬁed BoLA-DRB3*2703 in the presence of various concentrations of competing peptides.
The concentrations of non-self peptide required to inhibit self-peptide binding by 50% (IC50)
were variable, ranging from 26.92 to > 320 mM. Peptide-speciﬁc T-lymphocyte function
was determined by measuring DNA synthesis, cell division, and IFN-g production in cultures
of mononuclear cells from a BoLA-DRB3*2703 homozygous cow. When compared to non-
stimulated control cultures, differences in lymphocyte function were observed for all of the
assessed parameters; however, peptide-binding afﬁnity did not always account for the observed
differences in lymphocyte function.
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1. INTRODUCTION
The major histocompatibility complex (MHC) class I and II molecules
are immunoregulatory cell surface glycoproteins, which bind to and present
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antigenic peptides to T cells. Allelic variants are associated with speciﬁc
diseases in all mammals, including cattle. The highly polymorphic bovine
MHC (BoLA)-DRB gene, for example, has been implicated in the resistance
andsusceptibilitytobovineleukemiavirus[33],dermatophilosis[15]andmast-
itis [15,24]. In one study of Canadian Holsteins, BoLA-DRB3*1501/02 and
2703 alleles were associated with lower somatic cell scores and the occurrence
of clinical mastitis, respectively [24]. Certain amino acid motifs found within
the binding site, speciﬁcally in pocket four of the antigen-binding groove of
variousBoLA-DRB3 alleles,were laterdemonstratedtoconfersusceptibilityto
Staphylococcusspp. mastitis,possiblybyalteringBoLA-DRB-peptidebinding
afﬁnity [23].
In mice and humans, distinctive cytokine patterns [T helper 1 (Th1) vs.
T helper2 (Th2)], which affectdiseaseoutcome, are produced in the context of
interactions between MHC and various peptides [19]. It has been established
that while high afﬁnity ligands for MHC class II (e.g. HLA DRA*0101) [10]
mayinduceThelpercellstosecreteIFN-g andIL-2(Th1response),lowafﬁnity
ligands can induce IL-4 and IL-5 (Th2 response) [13,19]. It is speculated that
high afﬁnity interactions between peptides and MHC molecules can lead to
increase in the number of stable MHC-peptide complexes on the surface of
the antigenpresentingcells, which augment the avidityof MHC-peptide-T-cell
receptor (TCR) interactions [13]. It is plausible that susceptibility to bovine
mastitismaybeattributed,inpart,toinappropriateTh1/Th2immuneresponses
resulting from differences in BoLA-peptide binding afﬁnity that are governed
by allelic variants of BoLA class II genes. The present study was designed
to begin to address this possibility by (1) determining the binding afﬁnities
of various synthetic peptides from the core region of ovalbumin (OVA) and
two foot-and mouth disease virus (FMD-V) peptides, VP-2 and VP-4, for the
bindinggrooveencodedbythemastitissusceptibilityalleleBoLA-DRB3*2703,
and(2)determiningwhetherBoLA-DRB3-peptidebindingafﬁnityinﬂuencesT-
lymphocytefunctionasdeterminedbymeasuringDNAsynthesis,celldivision,
and IFN-g production.
2. MATERIALS AND METHODS
2.1. Peptides
Peptides were prepared by standard Fmoc solid phase chemistry and their
identitywasconﬁrmedbymassspectrometry. Severalself-peptides(BoLA-DQ
and ﬁbrinogen fragments), and non-self peptides (sperm whale myoglobin and
mycobacterium heat shock protein fragments) previously eluted from BoLA-
DRB3*2703 molecules were selected for initial study based on sequences
derivedfrommassspectrometryanalysisofpooledpeptides[26]. Theassump-
tion being that one or more of these peptides would bind with high afﬁnity toPeptide binding afﬁnity to the BoLA-DRB3*2703 allele S53
Table I. Peptides sequences and their respective concentration required to inhibit
BoLA class II-self-peptide binding by 50% (IC50).
Peptide IC50 (mM)
Self-peptide DQ (DVNEFRAVTPLGRPDAE)1 16.06
OVA327T316−327U (SSAESLKISQAV)2 > 320
OVA332T322−332U (KISQAVHAAHA)2 NB
OVA335T323−335U (ISQAVHAAHAEIN)2 26.92
OVA336T325−336U (QAVHAAHAEINE)2 > 320
OVA339T323−339U (ISQAVHAAHAEINEAGR)2 72.22
FMD-VP2T74−88U (PFGHLTKLELPTDHH)1 NB
FMD-VP4T20−34U (SIINNYYMQQYQNSM)2 46.46
Note: OVA D ovalbumin; FMD-VP D foot-and-mouth disease-virus
peptide; NB D no binding; 1 Peptides Lab Queens University, Kingston,
Ont.; 2 Dalton Chemical Laboratories, Toronto, Ont.
the BoLA-DRB3.2*2703 molecule and could be used as the marker peptide
in the binding assays. Selected self-peptides were biotinylated at the N-
terminus after additional incorporation of 6-aminohexanoic acid as a spacer
during synthesis. Immunodominant peptides from the core region of ovalbu-
min, including OVA 323–339, OVA 316–327, OVA 325–336, OVA 322–332,
OVA 323–335 [17,22] and two viral peptides from the foot and mouth disease
virus (FMDV), including VP2 74–88 and VP4 20–34 [7] were synthesized as
competitor peptides (Tab. I).
2.2. BoLA class II-peptide binding assays
The BoLA class II-peptide binding assay was carried out as previously
described [7]. Brieﬂy, puriﬁed BoLA-DRB3*2703 molecules were incubated
with 10 mM of either biotinylated self-peptide DQ or ﬁbrinogen [23], and
a non-labeled synthetic competitor peptide (Tab. I) ranging in concentration
from 0–640 mM. Biotinylated peptides were detected by enhanced chemi-
luminescence using the Western blot ECL enhancer (Amersham), Hyperﬁlm
ECL (Amersham), and a Konica ﬁlm processor. The relative band densities
were calculated using Scion Image software (NIH). These values were used to
calculatetheconcentrationof the competitorpeptidethatinhibitedself-peptide
binding by 50% (IC50) (Prism, GraphPad Software Inc.). Each binding assay
was repeated in two separate experiments. No differences were observed in
Western blot analysis and, therefore, data shown here are derived from one
representative experiment.S54 Z. Alizadeh et al.
2.3. Peptide sequence alignment
Since previous analysis of naturally processed peptides eluted from BoLA-
DRB3.2*2703 has provided some information about the binding speciﬁcity of
this allele [25], the OVA and FMD-V peptide sequences were aligned with the
BoLA-DQ self-peptide, eluted from BoLA-DRB3.2*2703 to identify similar
amino acid residues between the synthetic and self-peptide sequences using
the DIALIGN 2.1 program [18].
2.4. In vitro generation of peptide-speciﬁc T-lymphocytes
Blood-derived mononuclear cells (BMC) isolated from a Holstein cow
homozygous for the BoLA-DRB3*2703 were washed and suspended in cul-
ture medium (IMDM; Invitrogen life technologies, Burlington, Ont.) sup-
plemented with FCS, penicillin, streptomycin, and b-mercaptoethanol. BMC
were cultured as previously described with slight modiﬁcation [7]. Brieﬂy,
BMC were primed in vitro with various concentrations (0, 2.5, 5.0, 10.0
and 20:0 mg  mL−1) of synthetic peptides (Tab. I), and after 7 days viable
cells were enriched using the Shortman procedure [27], then cultured for an
additional 10 days in 10 mL of complete IMDM supplemented with 100 units
of recombinant human interleukin-2 (rhIL2; Serotec Inc., Raleigh, NC) to
generate peptide-speciﬁc lymphocytes ( 80% CD2C cells and no B-cells).
2.5. Analysis of lymphocyte DNA synthesis
Peptide-speciﬁc T-lymphocyte DNA synthesis was assessed by re-stimula-
ting the primed BMC with the same concentrationsof peptide in 3–5 replicates
per peptide per dose using BoLA-DRB3*2703-transfected L929 cells [26],
treated with mitomycin C (Sigma, 80 mg  mL−1), as antigen presenting cells
(APC). DNA synthesis was assessed after 5 days by measuring [3H] thymidine
incorporation (0:5 mCi) during the last 18 h of culture.
2.6. Analysis of cell division in T-lymphocyte sub-populations
BMC were labeled with carboxyﬂuorescein diacetate succinimidyl ester
(CFSE; Molecular Probes, Eugene, OR) as previously described [9]. Labeling
was performed just prior to in vitro peptide priming, at addition of rhIL2, and
at the time of peptide re-stimulation. Adherent-autologous BMC, treated with
mitomycin C (80 mg  mL−1), were used as APC for the peptide re-stimulation
phase. CD2C, CD4C and CD8C T-lymphocytes were identiﬁed using mono-
clonalantibodiesIL-A43,IL-A11,andIL-A105,respectively(ILRADNairobi,
Kenya), and then labeled with either biotinolated goat-anti-mouse F.ab/2 IgG
(HCL), or the respective isotype control, followed by streptavidin conjugatedPeptide binding afﬁnity to the BoLA-DRB3*2703 allele S55
phycoerythrin (PE; Cedarlane, Hornby, Ont.). The relative numbers of T-
lymphocyte divisions were assessed by ﬂow cytometry [12]. The CD4C and
CD8C T-cells with high and low ﬂuorescence intensities (CD4Chi, CD4Clo,
CD8Chi, CD8Clo) were deﬁned by comparison with the isotype control in the
FL2/FL1 mode. Cell viability as assessed by trypan blue exclusion after the
rhIL-2expansionphasewas> 90%. Lymphocytestimulationwiththemitogen,
concanavalin-A (Con-A, Sigma, 5 mg  mL−1) was used as a positive control.
2.7. T-lymphocyte interferon-g production
BMC were primed in vitro with OVA 335, 336, 339, or FMD-VP2 and VP4
peptides at a previously determined optimal antigen dose (5 mg  mL−1), then
expandedwithrhIL-2asdescribedabove. Peptide-speciﬁcT-lymphocyteswere
re-stimulatedwiththesameconcentrationofpeptideusingadherent-autologous
BMC, treated with mitomycin C as APC. Aliquots of culture supernatant
were removed 18 h after addition of rhIL-2 and at the peptide re-stimulation
phase to assess relative amounts of IFN-g produced by the peptide-speciﬁc
T-lymphocytes. Lymphocyte stimulation with Con-A (5 mg  mL−1) was used
as a positive control. Bovine IFN-g was measured by ELISA according to the
manufacturer’s protocol (CSL Veterinary Inc., Victoria, Australia).
2.8. Statistical analyses
Band densities from Western blots following competitive peptide-binding
assayswereplottedagainstpeptideconcentrationusingPrismsoftware(Graph-
Pad Software Inc.) to calculate the concentration of competitor peptide that
inhibited self-peptide binding by 50% (IC50).
Since variances for the DNA synthesis, IFN-g, and most of the cell division
data were homogeneous these data were analyzed by analysis of variance
(ANOVA) using the Prism software (GraphPad Software Inc.). When sig-
niﬁcant differences (P < 0:05) were observed between treatments, planned
contrastswereperformedwiththeDunnett’sT-test,usingthenaïve cells(BMC
that were neither primed, nor re-stimulated with the peptide) as the control
group. The Kruskal-Wallis Test was used to analyze the non-parametric cell
division data. When signiﬁcant differences (P < 0:05) in these data were
observed, contrasts were performed using the Dunn Test (GraphPad Software
Inc.).
3. RESULTS
3.1. BoLA class II-peptide binding assays
An initial binding assay was performed to identify which peptide(s) had the
highest BoLA-DRB3*2703 binding afﬁnity for use in the competitive bindingS56 Z. Alizadeh et al.
0 1 02 04 0 8 0 1 6 0 mM
40.6 31.4 15.1 9.0 4.7 0
A.
B.
Figure1. (A)ArepresentativepeptidebindingassayfortheBoLA-DRB3*2703classII
moleculeusingbiotinylatedﬁbrinogenself-peptide(10mM)atdifferentconcentrations
of the competitor self-peptide, BoLA-DQ, and (B) determination of the concentra-
tion of BoLA-DQ required to inhibit ﬁbrinogen-BoLA DRB3*2703 binding by 50%
(IC50).
assays. At an equivalent molarity, theband densityforthe BoLA-DQ fragment
(Density D 58:2 pixels) was slightlygreater than that of ﬁbrinogen (Density D
47:8 pixels). Both of these self-peptides had much higher binding afﬁnities
than two non-self peptides, HSP (Density D 9:1 pixels) and SPM (Density D
7:8 pixels), previously eluted from BoLA-DRB*2703.
Figure 1A is a representative illustration of one of the BoLA class II-
peptide binding assays. In this case, biotinylated ﬁbrinogen self-peptide
binding afﬁnity for BoLA-DRB3*2703 is shown in the presence of the com-
petitor DQ self-peptide. The concentrations of DQ self-peptide were plotted
against the ﬁbrinogen band intensity in order to determine the IC50 for DQ
as 16:06 mM (Fig. 1B). Based on these results, the BoLA-DQ peptide was
selected as the biotinylated self-peptide for the competitive binding assays
with OVA and FMD-V peptides. The IC50 for each of the synthetic com-
petitor peptides are listed in Table I. The BoLA-DRB3*2703-peptide binding
afﬁnities from the highest to lowest for the various synthetic peptides were;
OVA335 > FMD-VP4 > OVA339 > OVA 327, 336, and no binding could be
detected for OVA 332 and FMD-VP2 peptides.Peptide binding afﬁnity to the BoLA-DRB3*2703 allele S57
3.2. Peptide sequence alignment
Although, amino acid sequences associated with binding to BoLA-
DRB3*2703 werenotabsolute,complementarysequenceswerefoundbetween
some of the peptides, capable of binding to this allele, and the DQ peptide.
For the OVA peptides, complementary glutamic acid (E), isoleucine (I), aspar-
agine (N) and E were found at positions 333, 334, 335 and 336, respectively.
These amino acids aligned with amino acids of similar characteristics, aspartic
acid (D), valine (V), N and E in the DQ peptide. The OVA 327 and OVA 332
peptides, which did not have this sequence similarity, bound weakly or not at
all to BoLA-DRB3*2703. The FMD-VP4 peptide, with high binding afﬁnity
to BoLA-DRB3*2703, also had a sequence which is complementary to the N,
E, phenylalanine (F) and arginine (R) sequence of the DQ. The FMD-VP2
peptide, which was not able to bind to BoLA-DRB3*2703, had complementary
sequences with other regions of the DQ peptide (Tab. I).
3.3. DNA synthesis
Whencomparedtonaïvecellcultures(non-stimulatedBMC),atvariouscon-
centrations the OVA 335 (2.5–20:0 mg  mL−1) and OVA 339 (5:0 mg  mL−1)
peptides, which have relatively high binding afﬁnities, stimulated signiﬁc-
ant DNA synthesis of T-cells following peptide priming and re-stimulation
(Tab. II). Conversely, OVA 327 (5.0–10:0 mg  mL−1) and FMD-VP4 (2.5–
20:0 mg  mL−1) peptides, with low and high binding afﬁnities respectively,
when used at various concentrations, were associated with signiﬁcantly lower
T-lymphocyte DNA synthesis compared to BMC controls (Tab. II). DNA
synthesis in the OVA 332, 336 and FMD-VP2 cultures was not signiﬁcantly
different from the control. All re-stimulated T-lymphocytes plus APC cultures
respondedwithincreasedDNAsynthesiswhencomparedtothepeptide-primed
T-lymphocytes, without APC.
3.4. Cell division in T-lymphocyte sub-populations
Cell division was evaluated during the production of peptide-speciﬁc T-
lymphocytes at a previously determined optimal antigen dose (5 mg  mL−1).
During the 7-day in vitro peptide priming phase, signiﬁcant differences in cell
divisionwerenotobserved. However, afterthe10-dayrhIL-2expansionphase,
signiﬁcantly(P < 0:05) moreCD4Chi and lo andCD8Chi and lo T-celldivisionwas
observed in the FMD-VP2, and VP4 peptide-speciﬁc T-lymphocyte cultures,
when compared to the naïve lymphocyte culture.
Following T-lymphocyte re-stimulation with peptide, using adherent-
autologous BMC as APC, signiﬁcant (P < 0:05) differences in cell divi-
sion were also observed for speciﬁc T-lymphocyte sub-populations (Fig. 2).S58 Z. Alizadeh et al.
Table II. Lymphocyte DNA synthesis following re-stimulation with peptide using
BoLA transfected L-cells as antigen presenting cells.
Peptide
concentration
(mg  mL−1)
02 . 5 5 1 02 0
OVA327 1414  104 1254  69 874  70 1110  62 1537  45
OVA332 634  52 722  99 671  54 804  38 689  56
OVA335 1153  69 515  105 3081  139 5006  97 3892  303
OVA336 927  53 1117  65 1031  74 1015  124 920  34
OVA339 437  58 316  30 1104  142 374  58 302  34
FMD-VP2 1315  374 1874  169 2026  164 4399  2055 1090  149
FMD-VP4 2839  184 1155  283 2044  244 2241  141 650  35
Note: Data are presented as the mean  SE cpm at each peptide concentration. Data
that are signiﬁcantly different from the naïve cultures are representedby  (P  0:05)
and  (P  0:01). These data are representative of two repeated assays for each
peptide.
Less cell division, for example, was observed in all of the peptide-speciﬁc
cultures for the CD8Chi T-lymphocyte population, when compared to the
naïve lymphocyte culture; whereas, more cell divisions were observed for the
OVA336andOVA339peptide-speciﬁcCD8CloT-lymphocytes(Tab.III). More
cell divisions were also observed in the CD4Chi T-lymphocyte sub-population
in all but the FMD-VP4 peptide-speciﬁc cultures, but not in the CD4Clo sub-
population (Fig. 2, Tab. III).
3.5. T-lymphocyte interferon-g (IFN-g) production
Lymphocyte function, assessed by measuring the ability of the various
peptide-speciﬁcT-lymphocytestoproduceIFN-g,indicatedthatOVA335,336,
339, and FMD-VP2 stimulated culture supernatants contained less (P < 0:05)
IFN-g than the supernatant from the naïve cell culture 18 h into the rhIL-2
expansion phase. IFN-g in the FMD-VP4 culture supernatant was not signiﬁc-
antly(P < 0:05)differentfromthosemeasuredinthenaïveculturesupernatant
atthistimepoint(datanotshown). Similar,butmoredramatic,differenceswere
observed after the various peptide-speciﬁc T-lymphocytes were re-stimulated
withthepeptideusingadherent-autologousBMCasAPC(Fig.3). Ineachcase
(T-lymphocytes alone and T-lymphocytes re-stimulated with APC C=− pep-
tide) OVA 335 and 336 peptide-stimulated cultures, contained less (P < 0:01)
IFN-g than the naïve cell culture (Fig. 3, Tab. III). The FMD-VP2 and
OVA339peptide-stimulatedculturesalsocontainedless(P < 0:05)IFN-g than
the naïve culture, but only when FMD-VP2 peptide-speciﬁc T-lymphocytesP
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Figure 2. Percentage of CD8C high (A) and low (B), and CD4C high (C) and low (D) peptide-speciﬁc T-lymphocytes at various stages
ofcell divisionafter ﬁve days of re-stimulation with peptide using adherent-autologous BMCasAPC. The percentage of peptide-speciﬁc
lymphocytes within each gated region was compared to the corresponding percentage of naïve lymphocytes to determine statistical
signiﬁcance (DP  0:05,  D P  0:01). Data are presented as the mean  SE.S60 Z. Alizadeh et al.
TableIII. Synopsisofpeptide-DRB3*2703bindingafﬁnitiesandT-lymphocytefunc-
tions following in vitro priming and subsequent re-stimulation with peptide.
Synthetic
peptide
Binding
afﬁnitya
DNA
synthesisb
Cell divisionc IFN-g d
CD4Chi CD4Clo CD8Chi CD8Clo
OVA 327 Low # –––––
O V A 3 3 2 L o wN D –––––
OVA 335 High "" ND # ND #
OVA 336 Low ND " ND #"#
OVA 339 High "" ND #"#
VP-2 Low ND " ND ###
VP-4 High # ND ND # ND "
Note: Arrows represent signiﬁcant (P  0:05) increases or decreases as compared
to the naïve (no peptide-priming and re-stimulation) blood mononuclear cell (BMC)
control. ND D no difference as compared to the naïve BMC control. a Designated
high and low peptide binding afﬁnities for BoLA-DRB3*2703 are determined based
on comparison to the high binding self peptide BoLA-DQ (Tab. I). b DNA synthesis
based on 3H-thymidine incorporation was used as an indicator of lymphocyte pro-
liferation. c The relative number of cell divisions following peptide re-stimulation
was assessed by labeling with carboxyﬂuorescein diacetate succinimidyl ester dye.
Lympocyte sub-populations were determinedusinganti-bovine CDmonoclonalanti-
bodies. d Bovine interferon-g was determined using a commercial ELISA test.
were cultured alone, and when OVA 339 peptide-speciﬁc T-lymphocytes were
re-stimulated with APCs plus peptide. When FMD-VP4 peptide-speciﬁc T-
lymphocytes were cultured alone and re-stimulated with APC C=− peptide,
IFN-g wasdramaticallygreater(P < 0:01)thanthosemeasuredinthenaïvecell
culture (Fig. 3). For all cultures, IFN-g was the greatest when T-lymphocytes
were cultured alone. With the exception of FMD-VP4, the Con-A positive
control enhanced IFN-g production for all of the different peptide-primed
cultures (Fig. 3).
4. DISCUSSION
Polymorphicresidueswithinthepeptide-bindingcleftofMHCareimportant
for peptide binding afﬁnity and speciﬁcity and therefore, regulate T-cell recog-
nition by inﬂuencing either MHC-peptide or MHC-TCR interactions [32].
It has been established for mice and man that while high afﬁnity ligands
for MHC class II molecules may induce T helper cells to secrete IFN-g
(Th1 response) [10], low afﬁnity ligands may induce the secretion of IL-4
and IL-5 (Th2 response) [13,19]. In addition to playing different roles inPeptide binding afﬁnity to the BoLA-DRB3*2703 allele S61
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Figure 3. Relative concentration of IFN-g in the supernatants of various peptide-
speciﬁc T-lymphocyte cultures. IFN-g was measured in lymphocyte culture super-
natants, 18 h after re-stimulated with and without peptide using adherent-autologous
BMC as APC, in peptide-primed T-lymphocytes alone, and in peptide-primed T-
lymphocytes that were re-stimulated with Con-A. For each treatment, IFN-g in the
peptide-speciﬁc lymphocyte cultures was compared to the corresponding amount in
the naïve lymphocyte cultures. Data are presented as the mean optical density 
dilution factor  SE. (DP  0:05,  D P  0:01).
host defense, inappropriate Th1/Th2 responses have also been associated with
certain diseases [21].
Understanding immune responses in MHC-deﬁned cattle may shed light on
the underlying mechanisms that lead to MHC-associated disease resistance,
and effective peptide vaccines. To enhance our understanding of the molecular
interactions between bovine MHC II and peptides, the present study sought
to determine the binding afﬁnities of various synthetic OVA and FMD-V
peptides to BoLA-DRB3*2703, an allele previously associated with mastitis
susceptibility. T-lymphocyte function was also assessed as a means of deﬁning
peptide presentation, and recognition by the T-cell receptor.
Various OVA and FMD-V peptides have previously been used as immun-
ogenic epitopes to deﬁne antigen presentation, the kinetics of peptide-MHC
binding,andassessantibodyresponsesofcattleandmice[3,4,7,11,17,22,31].
FMD-VP2 and VP4, for example, were both demonstrated to bind with highS62 Z. Alizadeh et al.
afﬁnity to BoLA-DRB3*1101 and BoLA-DRB3*0201, respectively. Moreover,
theirhighbindingafﬁnitywasconsistentwiththeirabilitytostimulatelympho-
cyteproliferation[7]. Inthe presentstudy, OVA peptidesweredemonstratedto
have binding afﬁnity for BoLA-DRB3*2703 ranging from 26.92 to > 320 mM.
DRB3*2703 binding afﬁnity of FMD-VP2 was not detectable, and VP4 had
a binding afﬁnity of 46:46 mM. Following re-stimulation of T-lymphocytes,
the high afﬁnity peptides, OVA 339 and 335, were associated with signiﬁc-
antly increased DNA synthesis and cell division of CD4Chi lymphocytes, but
decreased IFN-g production compared to the naïve cell controls (Tab. III).
On the contrary, the high DRB*2703-binding FMD-VP4 peptide was not
associated with increased DNA synthesis or cell division, but had signiﬁcantly
greater IFN-g compared to the naïve control. Following re-stimulation of T-
lymphocytes, peptides with lower DRB*2703-binding afﬁnities tended to have
lower or no differences in DNA synthesis, cell division and IFN-g production
(Tab. III). A greater number and variety of peptides will need to be studied
to conﬁrm any associations between peptide binding afﬁnities for DRB3*2703
and T-cell function.
The analysis of the MHC class II eluted peptides has generally been less
informative than the analysis of MHC class I-associated peptides because they
are more variable in length, can extend beyond the binding groove, and may
not have identiﬁed anchor residues [1]. Additionally, most of the binding
energyoriginatesfromthe a-carbonbackboneof the peptidesfor MHCclassII
molecules, whereas for MHC class I molecules, the binding energy is derived
from the interaction between a few peptide anchor residue side chains and the
MHC pocket [5,28]. Taken together, these data suggest that instead of using
simple motifs to assess the probable contribution of each peptide residue to
MHC II binding, a different approach, possibly utilising a computer scoring
algorithm to scan proteins and to create a hierarchy of likely peptide ligands,
may be required [5,8].
Although these data suggest some association between high or low peptide
binding afﬁnity for BoLA-DRB3*2703 and differences in T-lymphocyte func-
tion (Tab. III), it is not absolute. This may not be surprising, since the peptides
used in this study were ranked according to their binding afﬁnity for the BoLA-
DRB3*2703 molecule, alone. Other variables including, peptide degradation,
binding afﬁnity for the T-cell receptor, expression of co-stimulatory and adhe-
sion molecules, T-cell receptor avidity, surface density of MHC class II-T-cell
receptorcomplexes,cell-cycleandlengthofdifferentiationtimehavealsobeen
demonstratedtoinﬂuenceMHCclassII-T-cellreceptormediatedT-lymphocyte
function[2,6,11,16,20,29,30]. OurinitialinterpretationofthedecreasedDNA
synthesis in the FMD-VP4 (high binding) peptide-speciﬁc T-lymphocytes was
that there might be a hole in the T-cell repertoire. However, the high levels of
IFN-g production by this lymphocyte culture clearly indicate that this is notPeptide binding afﬁnity to the BoLA-DRB3*2703 allele S63
the case. This may be an example whereby T-cell effector cytokine expression
was attained independently of the cell cycle [14]. It is also possible that the
OVA 339 and FMD-VP2 cultures, which produced relativelylittleIFN-g, were
actually Th2 polarized sub-populations [6].
5. CONCLUSION
The present study determined the binding afﬁnities of several OVA and
FMD-V peptides for BoLA-DRB3*2703. Although these peptides elicited
uniqueT-lymphocyteresponsesandeffectorcytokineproduction,itisnotabso-
lutely clear that high and low peptide binding afﬁnity for BoLA-DRB3*2703
alone accounts for observed differences in T-lymphocyte function.
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